
|Articles|July 31, 2006
Fourth indication approved for gemcitabine
Women with recurrent ovarian cancer will now have a new therapy option. Gemcitabine (Gemzar, Lilly) has been approved for use in combination with carboplatin for advanced ovarian cancer that has relapsed at least six months after initial therapy.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
Pharmacist Involvement Speeds Prior Authorization for GLP-1s
2
Navigating Compounding Peptides and GLP-1s Through Regulations
3
The 2026 GLP-1 Compounding Crackdown: A Pharmacist’s Guide
4
Understanding the Restructure of US Pharmacy Benefits Amid Reform, Regulatory Action
5


























